Industry Symposium:
A CDK4/6i is a ‘once in a lifetime treatment’ for patients with
HR +ve HER2 -ve breast cancer
Supported by Novartis
Saturday, October 15, 2022 Hall B (Great Hall 2)
10:00 – 11:00
Admission to this symposium is included as part of the congress registration
| Chairperson: | Nicholas Wilcken, Sydney, Australia |
| Introduction Richard de Boer, Melbourne, Australia |
|
| Debaters: | |
| Affirmative: Catherine Shannon, Brisbane, Australia | |
| Against: Andrew Redfern, Perth, Australia |